phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

This post has been updated as of 10/30/2017 to reflect relief efforts for Hurricanes Harvey, Irma and Maria.

Given the unprecedented scale of the devastation and flooding caused by Hurricanes Harvey, Irma and Maria, we wanted to provide information about the resources available for patients to access medicines as well as details about where to provide support and what some of America's biopharmaceutical companies are doing to respond to this tragedy.

Hurricane-Harvey.jpgTo support disaster recovery efforts, Healthcare Ready, an organization of private health care stakeholders and government response entities, is coordinating with local and federal agencies to ensure that medical gaps in the areas impacted by the hurricanes are addressed. Healthcare Ready’s Rx Open map has been turned on and will provide pharmacy status information for Alabama, Florida, Georgia, Louisiana, Puerto Rico, South Carolina and Texas. Sign up for notifications to stay current on their activities here.

The Partnership for Prescription Assistance is also helping connect individuals with patient assistance programs to replace lost medicines. Get prescription help here.

Here’s what some companies are doing to help and ways you can help support. We will continue to update this list.

  • AbbVie medicines were pre-positioned in 39 clinics across states and islands impacted by Hurricanes Harvey, Irma and Maria through Direct Relief.  AbbVie and the AbbVie Foundation have committed more than $4 million in grant funding and product donations for disaster response following the hurricanes. Grants support partners working in the affected regions in the U.S. and the Caribbean, including the American Red Cross, AmeriCares, Direct Relief International, Feeding America, Heart to Heart International, MAP International, International Medical Corps and Texas Children’s Hospital. Additionally, the AbbVie Foundation is matching employee donations to many relief organizations, including those listed above. Read AbbVie’s full announcement regarding hurricane relief here. 
  • Allergan plc announced that the Allergan Foundation will donate $100,000 to the American Red Cross to help victims of Hurricane Harvey. The Company is also working closely with Direct Relief International and MAP International to determine the need for product donations in affected areas. Read Allergan’s full announcement here.
  • Amgen Inc. announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico and has committed up to an additional $2 million for longer-term rebuilding efforts. The safety of the more than 2,000 Amgen employees and their families on the island remains a top priority for Amgen, and outreach to impacted staff is ongoing. In addition, the Amgen Foundation has donated a total of $160,000 to Direct Relief to support their work assisting community health centers devastated by Hurricane Harvey and Hurricane Irma, and $40,000 to the American Kidney Fund’s Disaster Relief Program to assist dialysis patients in Texas and Florida. They are also mobilizing a disaster relief matching gift program. Read Amgen’s full announcement on their Hurricane Maria response here and read the Amgen Foundation’s statement on disaster relief efforts here.
  • AstraZeneca Pharmaceuticals LP has made a national corporate contribution to the American Red Cross as part of their Corporate Disaster Responder program, and they are making a $100,000 contribution to Americares in support of their efforts specific to Hurricane Harvey and the Gulf Coast. AstraZeneca employees wishing to contribute support either financially or through volunteer efforts may do so through the company’s employee giving program. Employee donations to eligible U.S.-based organizations (such as the American Red Cross and others) will be matched at 100% by the company, and AstraZeneca employees may be eligible for paid volunteer leave at the discretion of their manager. Additionally, AstraZeneca is working with Americares and Direct Relief International to determine need for product donations with medicines prepositioned for use in the Gulf Coast.
  • Alexion Pharmaceuticals, Inc. plans to host an employee fundraiser and match all funds raised towards Harvey relief efforts up to $10,000. Their partner for this endeavor is Americares.
  • Bayer is committing $100,000 to Direct Relief International and $100,000 to the American Red Cross. This new donation is in addition to the $100,000 that Bayer provides to the American Red Cross annually for disaster preparedness. They are also working closely with non-profit partners to determine the need for product donations in affected areas.
  • Biogen announced that the Biogen Foundation has initiated their Disaster Response enhanced matching gift program. Between now and Friday, September 8, when U.S. Biogen employees make a contribution of $50 or more to the American Red Cross, the Biogen Foundation will contribute $3 for every $1 donated. They have raised $170,000 and anticipate this amount to grow over the next few weeks.
  • Boehringer Ingelheim Pharmaceuticals, Inc. announced that the Boehringer Ingelheim Cares Foundation is donating more than $125,000, as well as product donations as needed, to support relief efforts. Included in that contribution is a $25,000 donation to a local organization that is assisting animals affected by the storm. BI Cares is also supporting Americares and Direct Relief International, and Boehringer Ingelheim Animal Health has activated their Disaster Aid Program to provide aid for their veterinary customers that have severe damage or total loss of ability to practice in their facilities due to this disaster. Additionally, BI employees have raised over $30,000 for Americares, and the company has added special patient-centric provisions to their BI Cares Patient Assistance Program that allow enrolled patients in the Hurricane Harvey affected areas to obtain the medications they need urgently in order to stay adherent.
  • Bristol-Myers Squibb Company is donating medicines with a wholesale value of $10,414,000 to a network of the company’s global relief partners to support their efforts. In addition, the Bristol-Myers Squibb Foundation has donated a total of $2.1 million to hurricane recovery efforts, supporting organizations such as Americares, the American Red Cross, the Central Florida Red Cross chapter, the Puerto Rican Red Cross chapter and Direct Relief International. Additionally, the Bristol-Myers Squibb Foundation is matching U.S. and Puerto Rican employee donations to all eligible organizations working on the relief efforts. Read Bristol-Myers Squibb’s full announcement here.
  • Daiichi Sankyo, Inc. provided direct financial assistance to the American Red Cross, and supplies of certain Daiichi Sankyo hypertension medicines recently donated to Americares have been sent to the super shelter in the Roger Brown convention center to assist individuals affected by Hurricane Harvey. Daiichi Sankyo employees wishing to donate to Americares toward the recovery effort may do so through a special Americares microsite set up for Daiichi Sankyo. Donations to Americares and other qualified non-profit organizations will be matched through the company’s matching gift program.
  • Eli Lilly and Company and the Eli Lilly and Company Foundation have committed nearly $7 million in medicines and more than $1 million in cash in response to the 2017 hurricane season. Earlier this year, Lilly donated medicines to Direct Relief International as part of the organization’s hurricane preparedness program. Lilly also donated 20,000 units of insulin and other diabetes products in the wake of hurricanes Harvey and Irma and is matching employee donations through the foundation. In Puerto Rico, Lilly is working to meet the urgent needs of its employees and their families, including financial assistance for shelter. Lilly flew an emergency shipment of insulin and supplies to Puerto Rico on September 24. The shipment included nearly 2,400 insulin vials and pens, which will treat about 1,000 people for 30 days. It also included glucagon and emergency supplies for employees, including food, water, batteries, generators and childcare items such as diapers. The company continues to monitor the situation in all of the affected communities and will consider additional action to help people in need.

  • EMD Serono made donations to the Red Cross and Houston Food Bank to support relief efforts. In addition, EMD Serono employees have been directed to official channels to provide assistance on their own, using the company matching program for further impact.
  • GlaxoSmithKline announced a pledge of $1 million to support relief efforts in Texas. These funds will be distributed over time to agencies supporting the relief and recovery in impacted communities. Working with Americares and Direct Relief International, GSK is also providing critical medicines, vaccines and consumer healthcare products to support those affected by Hurricane Harvey. GSK has a longstanding global commitment to supporting NGO partners in disaster situations including a $2 million grant to fund a joint Save the Children-Columbia University National Center for Disaster Preparedness three-year initiative to help US communities better prepare for disaster situations like that impacting the Houston area. Through GSK’s partnership with Save the Children, hundreds of thousands of employee-raised funds have gone to support their response to emergencies such as Hurricane Harvey.  All of these funds and other employee donations to relief organizations are fully matched by the company. 
  • Johnson & Johnson is working with three key partners on the ground in Texas: Americares, which is providing medicine and medical assistance to emergency shelters; Heart to Heart International, Inc., an organization that is deploying a mobile medical unit and supplies; and Save the Children, dedicated to children’s health and well-being. Americares and Heart to Heart are distributing 25,000 Johnson & Johnson hygiene kits stocked with soap, shampoo, toothpaste and other personal care items to emergency shelters and aid distribution centers. Johnson & Johnson customer and logistics services and supply chain teams are working to ensure a reliable supply of products, and their DePuy Synthes regional trauma teams are on the ground working to identify customer needs throughout the region. Additionally, Johnson & Johnson employees in the U.S. are also encouraged to donate through “Click to Care,” the J&J employee giving program in which donations to the company’s disaster relief partners and many other community organizations are matched at a two-to-one ratio. And, for every photo donated through their Donate a Photo app, Johnson & Johnson gives $1 to Heart to Heart International, Inc. That $1 allows Heart to Heart to distribute critical hygiene items to survivors in Texas, and it takes 10 photos to provide hygiene items to one Hurricane Harvey survivor. Donate a Photo is a free app and is available at app stores for both Droid and iPhone devices. Read J&J’s full announcement here.
  • Lundbeck is donating $25,000 to the American Red Cross and is matching employee donations to disaster relief up to $10,000. Lundbeck will also make additional donations to support their various disease communities impacted by the hurricanes, including $25,000 to the American Epilepsy Society to help support patients in affected areas, $25,000 to the National Alliance on Mental Illness (NAMI) to provide NAMI affiliates with assistance to support individuals and families affected by serious mental illnesses devastated by the hurricanes, $25,000 to the Alzheimer’s Association to help support individuals and families impacted by the storms, and $25,000 to the Parkinson’s Foundation to help those with Parkinson’s affected by the hurricanes. Lundbeck has made an additional $25,000 donation to the American Red Cross for relief efforts in Puerto Rico and is shipping epilepsy products to a major hospital on the island that is in need of supplies.

  • Merck & Co., Inc. has put forward a collective effort to help those impacted by Hurricanes Harvey, Irma and Maria. The company’s initial support was through the annual disaster relief support to the American Red Cross in the amount of $600,000, allowing the Red Cross to move quickly to respond to these and other disasters. Merck also announced a donation of $1 million to the Hand in Hand Hurricane Relief Fund as part of the “Hand in Hand: A Benefit for Hurricane Relief” television fundraiser, and provided an additional $250,000 in grants to Direct Relief, Americares, Project HOPE, Save the Children and World Vision. In addition to financial support, Merck has donated over $2.7 million worth of medicines, vaccines, animal health products, services and professional/technical support, which have already arrived in the affected areas.  Merck is matching 100% of donations from U.S. Merck employees to eligible nonprofit organizations directly supporting relief efforts. For further updates, see http://www.merck.com.
  • Novartis Pharmaceuticals Corporation equipped associates with emergency preparedness resources prior to the hurricane’s arrival and is now working to provide additional support to displaced associates, including using travel resources as an additional means to help associates evacuate from the affected areas and offering the Fort Worth campus as a safe place to work, shower and eat. They are also working to implement business continuity plans to ensure patients and medical professionals have continued access to medical devices and pharmaceutical products. In addition, they are donating $100,000 to the American Red Cross to support Hurricane Harvey relief efforts, and are donating over $1 million in product donation to support impacted patients. Lastly, Novartis’ associate donations will be matched $1 for $1 with a maximum of $5,000 per associate per year across all giving programs. To date, employees and company match contribution to the disaster totals over $144,000. Employees will continue to make employee contributions to the disaster efforts during the company’s annual six week Charitable Giving Campaign that kicks off in October.
  • Novo Nordisk Inc. is working on the ground with long-time disaster relief partner, Americares, to donate products (including medicines) to non-profit organizations. The company is dedicated to providing relief to impacted employees in the form of time off, product assistance, household relief and financial assistance as necessary for clothing, food and other items. They are also matching employee contributions to the American Red Cross and are pledging $150,000 to the local Houston Health Foundation. Read more about Novo Nordisk’s efforts here.
  • Pfizer Inc. announced that a comprehensive disaster relief effort has been implemented, including the following activities: (1) the Pfizer Foundation has made significant cash grants to key organizations leading relief efforts on the ground, including the American Red Cross, World Vision, and Americares. (2) The Pfizer Foundation has implemented a special one-to-one to match for cash donations made by Pfizer colleagues to the American Red Cross for the relief efforts during the next month. (3) Donations of Pfizer prescription and consumer products are currently underway through Direct Relief and Americares, and Pfizer is prepared to make additional product donations to these organizations and others as needed. (4) Disaster protocols for its patient assistance programs in the affected areas have been activated:  waiving financial documentation requirements for new patients; allowing existing patients to request refills earlier; and enabling hospitals and clinics that participate in its bulk replenishment program to request additional product to replace inventory lost in the storm and/or to meet increased demand.
  • Sanofi US products, mostly insulin product and tetanus vaccines, were pre-positioned through our NGO partners, Direct Relief International and Americares, prior to the storm. Sanofi is currently fulfilling additional requests for insulin product and tetanus vaccines, and is expecting additional product requests from our NGO partners. Sanofi is also evaluating our over-the-counter portfolio to benefit World Vision’s hygiene kits. Counselors with the Sanofi Patient Connection program are assisting with replacement product needs for program patients impacted by Hurricane Harvey. The Sanofi Foundation for NA is donating $225,000 across Direct Relief International, Americares and Heart to Heart International, and the company is providing a special matching donation campaign through the end of September for employees, separate from their year-round program, to benefit the American Red Cross.  We have reached out and are assisting our employees in the impacted areas.
  • Takeda announced that it plans to provide $20,000 in grants for Hurricane Harvey disaster relief to the American Red Cross.  Takeda also is matching employee donations from its 5,000 employees across the U.S. to disaster relief organizations.
  • Teva Pharmaceuticals is working with the nonprofit organization Direct Relief to donate prepositioned and as-needed products. Additionally, Teva is working with the American Red Cross to offer global employees a donation platform through which donations will be matched by the company.
  • UCB’s patient- and healthcare provider-facing service center, UCBCares (1-844-599-CARE (2273)), is available 24/7 to take calls from patients in the affected areas in need of medicine as well as coordinating with local infusion centers and pharmacies to ensure continuity of care for patients. UCB is a proud supporter of the Red Cross and is kicking off an employee contribution drive to support Red Cross as well.

Holly Campbell

Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.

Holly Campbell

Author Twitter

Author LinkedIn

Staffing up: Building the future biopharma workforce to keep America in the lead

June 29, 2026

Nearly 80 researchers advocate on Capitol Hill

June 11, 2026

Congratulations to our 2026 Working for Cures Employee Champions

January 29, 2026

Manufacturing U.S. jobs and breakthroughs

October 6, 2025

Historic biopharmaceutical investments: A prescription for America’s future

September 29, 2025

Bringing to life the full story of biopharmaceutical innovation and investments

July 22, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

Congratulations to our 2024 Working for Cures Employee Champions

December 11, 2024

The importance of partnership: A conversation with Takeda

October 10, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

More than 60 researchers advocate on Capitol Hill

July 1, 2024

Alzheimer's & Brain Awareness Month: A conversation with Biogen

June 27, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eisai

June 24, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company

June 20, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

Congratulations to our 2023 Working for Cures Employee Champions

December 6, 2023

Watch: Putting patients front and center for World AIDS Day

November 30, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

Biopharmaceutical science powered by PRIDE

June 16, 2023

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

May 30, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

December 8, 2022

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

Congratulations to our 2022 Working for Cures Employee Champions

November 10, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

July 18, 2022

Biopharmaceutical researchers to discuss the value of R&D with Congress

June 9, 2022

A conversation with Barry Greene, CEO of Sage Therapeutics

May 4, 2022

Stephanie Dyson of BMS on reducing health disparities

April 27, 2022

Biopharmaceutical industry drives economic growth in all 50 states

March 14, 2022

Guest post: Joining forces to combat the COVID-19 mental health crisis

February 17, 2022

Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry

September 28, 2021

Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda

September 27, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

July 22, 2021

Watch: Building trust and enhancing clinical trial diversity

June 24, 2021

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

June 23, 2021

Researchers to shine light on biopharmaceutical R&D with policymakers

June 15, 2021

Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive

March 5, 2021

Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL

February 24, 2021

Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen

January 28, 2021

Report highlights biopharmaceutical industry’s commitment to D&I

December 17, 2020

Guest Post: Bringing our best to the fight against COVID-19

December 3, 2020

An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb

November 18, 2020

Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck

October 28, 2020

New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce

October 12, 2020

Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech

October 1, 2020

Leading researchers to spotlight the critical role of biopharmaceutical R&D

October 1, 2020

Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A

September 23, 2020

Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.

September 17, 2020

Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19

September 16, 2020

PhRMA member companies invested $83 billion in research and development last year

September 10, 2020

Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi

September 2, 2020

Three ways the pharmaceutical industry can positively impact health equity

September 1, 2020

ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

August 4, 2020

New report explores setbacks that bring future cancer success stories

July 16, 2020

In combating COVID-19, science is how we get back to normal

June 24, 2020

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

June 24, 2020

Guest Post: What will we learn from COVID-19?

May 27, 2020

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines

April 15, 2020

To the millions affected by COVID-19

April 9, 2020

Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19

April 6, 2020

The biopharmaceutical industry’s unique role in responding to COVID-19

April 2, 2020

ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus

April 1, 2020

COVID-19 Response: Supporting the frontline

March 30, 2020

Guest post: Looking out for the invisibly vulnerable in the time of COVID-19

March 26, 2020

America’s biopharmaceutical companies are working around the clock to beat coronavirus

March 20, 2020

Guest post: Takeda’s efforts to address COVID-19

March 19, 2020

ICYMI: America’s biopharmaceutical companies are taking on COVID-19

March 16, 2020

ICYMI: Continued biopharmaceutical action on COVID-19

March 6, 2020

Working together to combat coronavirus

February 6, 2020

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

May 9, 2019

PPA celebrates 13 years of helping patients access their medicines

April 5, 2018

The journey to better health care requires a holistic view

September 18, 2017

Celebrating PRIDE in biopharmaceutical science

June 1, 2017

Guest Post: The importance of a modern FDA in drug discovery

March 22, 2017

PPA: 2016 in review

February 23, 2017

Exploring the new era of medicine

February 21, 2017

Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?

February 15, 2017

Watch: Biomarkers in drug development with Dr. Bernie Zeiher

February 14, 2017

Helping those affected by the 2017 hurricane season

PhRMA Member Company

Partnership for Prescription Assistance

Helping those affected by the 2017 hurricane season

August 31, 2017

Helping those affected by the 2017 hurricane season

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list